RECEIVED
CENTRAL FAX CENTER
MAR 0 4 2005

FULBRIGHT & JAWORSKI L.L.P.
A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

FACSIMILE TRANSMISSION

DATE: March 4, 2005 **MATTER NUMBER:** 10313706

GOUD:040US

RECIPIENT:	FAX NO.:	PHONE NO.:
Commissioner for Patents U.S. Patent Office	703/872-9306	703/308-1202

FROM: Kellie Pfertner **USER ID:** 12096 **FLOOR:** 20

PHONE: (512) 536-5604 **FAX:** (512) 536-4598

RE: SIDS and Substitute Form PTO-1449

NUMBER OF PAGES WITH COVER PAGE: 6 Originals Will Not Follow

Message:

Please enter in the following matter:

U.S. Patent Application No. 10/693,657, entitled "*CYTOKINE RECEPTOR MODULATORS, METHOD OF IDENTIFYING SAME, AND METHOD OF MODULATING CYTOKINE RECEPTORS ACTIVITY WITH SAME*", by Sylvain Chemtob *et al.*

Thank you for your attention to this matter.

IF YOU DO NOT RECEIVE ALL OF THE PAGES, PLEASE CALL KELLIE PFERTNER @ 512/536-5604AS SOON AS POSSIBLE.

RECEIVED
CENTRAL FAX CENTER
MAR 0 4 2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Sylvain Chemtob *et al.*

Serial No.: 10/693,657

Filed: October 24, 2003

For: CYTOKINE RECEPTOR MODULATORS, METHOD OF IDENTIFYING SAME, AND METHOD OF MODULATING CYTOKINE RECEPTORS ACTIVITY WITH SAME

Group Art Unit: 1644

Examiner: Unknown

Atty. Dkt. No.: GOUD:040US

CERTIFICATE OF FACSIMILE TRANSMISSION
37 C.F.R. § 1.8

I hereby certify that this correspondence is being transmitted to: Commissioner for Patents, MS AMENDMENT; P.O. Box 1450, Alexandria , VA 22313-1450, facsimile number (703) 872-9306 on the date below:

March 4, 2005
Date

Michael R. Krawzsenek

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of references have previously been provided for the convenience of the Examiner. The Form PTO-1449 submitted on February 25, 2005 did not include page 3. Applicants request that the concurrently filed Form PTO-1449 replace the form filed on February 25, 2005.

In accordance with 37 C.F.R §§ 1.97(g), (h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/GOUD:040US.

Applicants respectfully request that the listed documents be made of record in the present case.

Respectfully submitted,

Michael R. Krawzsenek
Reg. No. 51,898
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 4, 2005

Form PTO-1449 (modified)	Atty. Docket No. GOUD:040US	Serial No. 10/693,657
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Sylvain Chemtob *et al.*	
	Filing Date: October 24, 2003	Group: 1644

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Baker *et al.*, "Cell proliferation kinetics of normal and tumour tissue in vitro: quiescent reproductive cells and the cycling reproductive fraction," *Cell Prolif.*, 28(1):1-15, 1995.
	C2	Brady and Dodson, "Reflections on a peptide," *Nature*, 368:692-693, 1994.
	C3	Carell *et al.*, "A novel procedure for the synthesis of libraries containing small organic molecules," *Angew Chem Int Ed Engl*, 33(20):2059-2061, 1994.
	C4	Cheviron *et al.*, "The antiproliferative activity of the tetra peptide acetyl-N-SerAspLysPro, an inhibitor of hematopoietic stem cell proliferation, is not mediated by a thymosin β4-like effect on actin assembly," *Cell Prolif.*, 29(8):437-446, 1996.
	C5	Cho *et al.*, "An unnatural biopolymer," *Science*, 261:1303-1305, 1993.
	C6	Coller *et al.*, "Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation," *J. Biol. Chem.*, 268:20741-20743, 1993.
	C7	Cull *et al.*, "Screening for receptor ligands using large libraries of peptides linked to the C terminus of the lac repressor," *Proc. Natl. Acad. Sci., USA*, 89:1865-1869, 1992.
	C8	DeWitt *et al.*, "'Diversomers': an approach to nonpeptide, nonoligomeric chemical diversity," *Proc. Natl. Acad. Sci., USA*, 90:6909-6913, 1993.
	C9	Elliot *et al.*, "Bin1 functionally interacts with myc and inhibits cell proliferation via multiple mechanisms," *Oncogene*, 18(24):3564-3573, 1999.

25359089.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. GOUD:040US	Serial No. 10/693,657
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Sylvain Chemtob *et al.*	
	Filing Date: October 24, 2003	Group: 1644

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C10	Erb *et al.*, "Recursive deconvolution of combinatorial chemical libraries," *Proc. Natl. Acad. Sci., USA*, 91:11422-11426, 1994.
	C11	Fodor *et al.*, "Multiplexed biochemical assays with biological chips," *Nature*, 364:555-556, 1993.
	C12	Gallop *et al.*, "Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries," *Journal of Medicinal Chemistry*, 37(9):1233-1251, 1994.
	C13	Houghten *et al.*, "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," *BioTechniques*, 13(3):412-421, 1992.
	C14	Hu *et al.*, "α_{1}-adrenergic receptor stimulation of mitogenesis in human vascular smooth muscle cells: role of tyrosine protein kinases and calcium in activation of mitogen-activated protein kinase[1]," *J. Pharmacol. Exp. Ther.*, 290(1):28-37, 1999.
	C15	Jameson *et al.*, "A rationally designed CD4 analogue inhibits experimental alergic encephalomyelitis," *Nature*, 368:744-746, 1994.
	C16	Lam *et al.*, "A new type of synthetic peptide library for identifying ligand-binding activity," *Nature*, 354:744-746, 1991.
	C17	Lam, "Application of combinatorial library methods in cancer research and drug discovery," *Anti-Cancer Drug Design*, 12:145-167, 1997.
	C18	Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," *J. Am. Chem. Soc.*, 85:2149-2154, 1964.
	C19	Piossek *et al.*, "Vascular endothelial growth factor (VEGF) receptor II-derived peptides inhibit VEGF,: *The Journal of Biological Chemistry*, 274(9):5612-5619, 1999.
	C20	Powell *et al.*, "Peptide stability in drug development. II. Effect of single amino acid substitution and glycosylation on peptide reactivity in human serum," *Pharmaceutical Res.*, 10(9):1268-1273, 1993.
	C21	Scott and Smith, "Searching for peptide ligands with an epitope library," *Science*, 249:386-390, 1990.
	C22	Tamaskovic *et al.*, "Enzyme-linked immunosorbent assay for the measurement of JNK activity in cell extracts," Biol. Chem, 380:569-578, 1999.

25359089.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. GOUD:040US	Serial No. 10/693,657
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Sylvain Chemtob *et al.*	
	Filing Date: October 24, 2003	Group: 1644

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 1*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Tan *et al.*, "A small peptide derived from flt-1 (VEGFR-1) functions as an angiogenic inhibitor," *FEBS Letters*, 494:150-156, 2001.
	C24	Vigers *et al.*, "X-ray crystal structure of a small antagonistic peptide bound to interleukin-1 receptor type 1," *J. Biol. Chem.*, 275(47):36927-36933, 2000.
	C25	Yoon *et al.*, "Antibodies to domains II and III of the IL-1 receptor accessory protein inhibit IL-1β activity but not binding: regulation of IL-1 responses is via type 1 receptor, not the accessory protein," *Journal of Immunology*, 3170-3179, 1998.
	C26	Zuckermann *et al.*, "Discovery of nanomolar ligands for 7-transmembrane G-protein-coupled receptors from a diverse N-(Substituted) glycine peptoid library," *J. Med. Chem*, 37:2678-2685, 1994.

25359089.1

EXAMINER:	DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.